Patheon to expand

Abstract

Still in the process of being acquired by Thermo Fisher for $7.2 billion, the drug services firm Patheon says it will spend $45 million to expand several sites in the U.S. and Europe. The investment continues the company’s push to establish a full-product life-cycle pharmaceutical service. Patheon will build a 1,400-m2 spray-drying facility at an active pharmaceutical ingredient plant in Florence, S.C., that it acquired from Roche last year. The firm will also add an analytical lab to its spray-drying operation in Bend, Ore. In Greenville, N.C., Patheon will expand packaging and serialization capabilities with a 445-m2 manufacturing line. In Monza, Italy, the company is adding commercial-scale sterile product facilities for large- and small-molecule drugs. At the same site, it is installing lyophilizers, a sterile vial filling line, and an analytical laboratory for its pharmaceutical development service. Patheon became an end-to-end drug services firm through the 2013 merger of DSM’s